Extremely promising Ebola vaccine

The World Health Organization (WHO) announced the preliminary results of an “extremely promising” vaccine against the deadly Ebola virus that has led to 100% protection and this development could greatly help prevent Ebola’s spread in current and future outbreaks.

The vaccine VSV-EBOV was developed by the Public Health Agency of Canada and it was licensed to NewLink Genetics Corporation, a NASDAQ-listed biopharmaceutical company. The Firm is humbled to represent NewLink Genetics Corporation in Japanese patent matters.”